MedTrace Logo

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

NCT03466502 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2023-11-28

No results posted yet for this study

Summary

This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.

Conditions

  • Clostridium Difficile Infection

Interventions

DRUG

Oral Vancomycin

Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence

Sponsors & Collaborators

  • Renown Regional Medical Center

    collaborator OTHER

  • University of Nevada, Reno

    lead OTHER

Principal Investigators

  • Lauren Zion, PharmD · Renown Regional Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-08
Primary Completion
2022-02-17
Completion
2022-02-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03466502 on ClinicalTrials.gov